Clinical relevance of galectin-1 expression in non-small cell lung cancer patients

Lung Cancer

Volumn 84, Issue 1, 2014, Pages 73-78

  Carlini, María José ^a   Roitman, Pablo ^b   Nuñez, Myriam ^b   Pallotta, María Guadalupe ^b   Boggio, Gastón ^b   Smith, David ^b   Salatino, Mariana ^c   Joffé, Elisa D Bal de Kier ^a   Rabinovich, Gabriel A ^c,d   Puricelli, Lydia I ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Biomarker; Galectin 1; Immunohistochemistry; Lung cancer; Prognosis; Survival

Indexed keywords

GALECTIN 1;

ADULT; AGED; ARTICLE; BLOOD VESSEL; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; STROMA CELL; TUMOR VASCULARIZATION; VERY ELDERLY;

BIOMARKER; GALECTIN-1; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PROGNOSIS; SURVIVAL;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GALECTIN 1; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR BURDEN;

EID: 84896723401     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.016     Document Type: Article

References (32)

1. Loria D., Lence Anta J.J., Guerra Yí M.E., Galán Álvarez Y., Barrios Herrera E., Alonso Barbeito R., et al. Tendencia de la mortalidad por cáncer en Argentina, Cuba y Uruguay en un período de 15 años. Rev Cubana Salud Púb 2010, 36(2):115-125.
2. Collins L.G., Haines C., Perkel R., Enck R.E. Lung cancer: diagnosis and management. Am Fam Physician 2007, 75(1):56-63.
3. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(8):706-714.
4. Tsuboi M., Ohira T., Saji H., Miyajima K., Kajiwara N., Uchida O., et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007, 13(2):73-77.
5. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
6. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6(1):24-37.
7. Rabinovich G.A., Croci D.O. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012, 36(3):322-335.
8. Juszczynski P., Ouyang J., Monti S., Rodig S.J., Takeyama K., Abramson J., et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007, 104(32):13134-13139.
9. Rubinstein N., Alvarez M., Zwirner N.W., Toscano M.A., Ilarregui J.M., Bravo A., et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004, 5(3):241-251.
10. Tang D., Yuan Z., Xue X., Lu Z., Zhang Y., Wang H., et al. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 2012, 130(10):2337-2348.
11. Kuo P.L., Huang M.S., Cheng D.E., Hung J.Y., Yang C.J., Chou S.H. Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem 2012, 287(13):9753-9764.
12. Banh A., Zhang J., Cao H., Bouley D.M., Kwok S., Kong C., et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 2011, 71(13):4423-4431.
13. Szöke T., Kayser K., Baumhakel J.D., Trojan I., Furak J., Tiszlavicz L., et al. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005, 69(2):167-174.
14. Szöke T., Kayser K., Kayser G., Furak J., Tiszlavicz L., Baumhäkel J.D., et al. The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur J Cardiothorac Surg 2007, 31(5):783-787.
15. Chen J., Zhou S.J., Zhang Y., Zhang G.Q., Zha T.Z., Feng Y.Z., et al. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol 2013, 19(13):2073-2079.
16. Kim H.J., Do I.G., Jeon H.K., Cho Y.J., Park Y.A., Choi J.J., et al. Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol 2013, 44(1):62-68.
17. Chen R., Pan S., Ottenhof N.A., de Wilde R.F., Wolfgang C.L., Lane Z., et al. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther 2012, 13(10):899-907.
18. Kamper P., Ludvigsen M., Bendix K., Hamilton-Dutoit S., Rabinovich G.A., Møller M.B., et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 2011, 117(24):6638-6649.
19. Wu H., Chen P., Liao R., Li Y.W., Yi Y., Wang J.X., et al. Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol 2012, 27(8):1312-1319.
20. Chung L.Y., Tang S.J., Sun G.H., Chou T.Y., Yeh T.S., Yu S.L., et al. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 2012, 18(15):4037-4047.
21. Rabinovich G.A., Toscano M.A. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009, 9(5):338-352.
22. Paz A., Haklai R., Elad-Sfadia G., Ballan E., Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001, 20(51):7486-7493.
23. Wu M.H., Hong T.M., Cheng H.W., Pan S.H., Liang Y.R., Hong H.C., et al. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res 2009, 7(3):311-318.
24. Hsu Y.L., Wu C.Y., Hung J.Y., Lin Y.S., Huang M.S., Kuo P.L. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013, 34(6):1370-1381.
25. Ito K., Ralph S.J. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clin Exp Metastasis 2012, 29(6):561-572.
26. Croci D.O., Salatino M., Rubinstein N., Cerliani J.P., Cavallin L.E., Leung H.J., et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012, 209(11):1985-2000.
27. Dalotto-Moreno T., Croci D.O., Cerliani J.P., Martinez-Allo V.C., Dergan-Dylon S., Méndez-Huergo S.P., et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 2013, 73(3):1107-1117.
28. Laderach D.J., Gentilini L.D., Giribaldi L., Delgado V.C., Nugnes L., Croci D.O., et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2013, 73(1):86-96.
29. Mathieu V., de Lassalle E.M., Toelen J., Mohr T., Bellahcène A., Van Goietsenoven G., et al. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol 2012, 132(9):2245-2254.
30. Thijssen V.L., Barkan B., Shoji H., Aries I.M., Mathieu V., Deltour L., et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010, 70(15):6216-6224.
31. Jung E.J., Moon H.G., Cho B.I., Jeong C.Y., Joo Y.T., Lee Y.J., et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007, 120(11):2331-2338.
32. Kadara H., Wistuba I.I. Field cancerization in non-small cell lung cancer: implications in disease pathogenesis. Proc Am Thorac Soc 2012, 9(2):38-42.